Clinical Trial Update: Rasburicase as a Uricolytic Therapy for Hyperuricemia in Patients With Leukemia or Lymphoma [Phase 2]

View source ↗

Summary

Phase 2 trial results evaluate rasburicase as a uricolytic therapy to treat hyperuricemia in patients with leukemia or lymphoma.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hyperuricemia
• Leukemia
• Lymphoma

Drugs mentioned

• Rasburicase (rasburicase)

Snippet

Sponsor: Sanofi | Conditions: Hyperuricemia, Leukemia | Phase 2 | Status: COMPLETED